Salt-induced gold nanoparticles aggregation lights up fluorescence of DNA-silver nanoclusters to monitor dual cancer markers carcinoembryonic antigen and carbohydrate antigen 125

Xu, Xin; Ji, Jiangrong; Chen, Panpan; Wu, Jiafeng; Jin, Can; Zhang, Liying; Du, Shouying

doi:10.1016/j.aca.2020.05.027

Cited by 51 publications

(21 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The squared correlation coefficient R 2 was determined to be 0.994, while the limit of detection (LOD) was determined to be 0.05 mU/mL with an S / N ratio of 3. The performance of this NIR-II ECL immunoassay was superior to those of the previously reported optical or electrochemical CA125 immunoassays. − …”

Section: Resultsmentioning

confidence: 77%

Surface-Defect-Induced and Synergetic-Effect-Enhanced NIR-II Electrochemiluminescence of Au–Ag Bimetallic Nanoclusters and Its Spectral Sensing

Gao

Dong

et al. 2021

Anal. Chem.

View full text Add to dashboard Cite

Aqueous electrochemiluminescence (ECL) in the second near-infrared biowindow (NIR-II, 900–1700 nm) was anticipated for ECL evolution and spectral multiplexing. Herein, aqueous and monochromatic ECL with a single emission peak beyond 900 nm was achieved by employing methionine (Met)-capped Au–Ag bimetallic nanoclusters (BNCs) as luminophores and triethanolamine (TEOA) as a coreactant. The Met-capped Au–Ag BNCs with surface-defect-induced PL around 756 nm were water-soluble and synthesized via doping Met-capped Au NCs with Ag in a doping-in-growth way. By extensively exploiting the red-shifting nature of surface-defect-induced ECL to PL and the synergetic-effect-enhanced ECL of BNCs, physically surface-confined Au–Ag BNCs exhibited efficient NIR-II ECL around 906 nm in aqueous medium. A spectrum-based NIR-II ECL immunoassay around 915 nm was also achieved by immobilizing the Au–Ag BNCs onto an electrode surface via forming a sandwich immunocomplex, which could selectively determine CA125 from 5 × 10–4 to 1 U/mL with a detection limit of 5 × 10–5 U/mL (S/N = 3). The combined strategy of surface-defect-induced ECL and synergetic-effect-enhanced ECL would enable promising biorelated application of NIR-II ECL.

show abstract

Section: Resultsmentioning

confidence: 77%

Surface-Defect-Induced and Synergetic-Effect-Enhanced NIR-II Electrochemiluminescence of Au–Ag Bimetallic Nanoclusters and Its Spectral Sensing

Gao

Dong

et al. 2021

Anal. Chem.

View full text Add to dashboard Cite

show abstract

“…Within the last 5 years, there has also been an emergence of studies reporting the use of aptamer-based systems for measuring serum CA125 as a means of achieving increased performance over traditional immunoassay methods [ 132 , 133 , 134 , 135 , 136 ]. In one study by Jin et al, the authors employed silver sulfide quantum dots (Ag 2 S QD) bound to negatively charged DNA/5-flurouracil aptamers to achieve detection of CA125 at concentrations as low as 0.07 ng/mL [ 135 ].…”

Section: Protein Diagnosticsmentioning

confidence: 99%

“…Their biosensors were able to detect CA125 down to 0.05 U/mL and STIP1 down to as low as 1 ng/mL, providing excellent analytical sensitivity and specificity for these two biomarkers. Similarly, Xu et al developed a dual-color aptasensor system for concurrent measurements of CA125 and CEA, in which analyte presence at threshold concentrations result in the aggregation of salt-induced gold nanoparticles leading to the formation of fluorescent analyte-silver nanoclusters [ 133 ]. Using this system, the authors demonstrated the ability to detect CA125 and CEA down to 0.015 U/mL and 7.5 pg/mL, respectively, in as little as 2 μL of serum [ 133 ].…”

Section: Protein Diagnosticsmentioning

confidence: 99%

“…Similarly, Xu et al developed a dual-color aptasensor system for concurrent measurements of CA125 and CEA, in which analyte presence at threshold concentrations result in the aggregation of salt-induced gold nanoparticles leading to the formation of fluorescent analyte-silver nanoclusters [ 133 ]. Using this system, the authors demonstrated the ability to detect CA125 and CEA down to 0.015 U/mL and 7.5 pg/mL, respectively, in as little as 2 μL of serum [ 133 ]. Farzin et al showed an even lower limit of detection for CA125 in human serum (0.0042 U/mL) using an alternative nanobiosensing platform [ 136 ].…”

Section: Protein Diagnosticsmentioning

confidence: 99%

See 1 more Smart Citation

Current and Emerging Methods for Ovarian Cancer Screening and Diagnostics: A Comprehensive Review

Liberto

Chen

Shih

et al. 2022

Cancers

View full text Add to dashboard Cite

With a 5-year survival rate of less than 50%, ovarian high-grade serous carcinoma (HGSC) is one of the most highly aggressive gynecological malignancies affecting women today. The high mortality rate of HGSC is largely attributable to delays in diagnosis, as most patients remain undiagnosed until the late stages of -disease. There are currently no recommended screening tests for ovarian cancer and there thus remains an urgent need for new diagnostic methods, particularly those that can detect the disease at early stages when clinical intervention remains effective. While diagnostics for ovarian cancer share many of the same technical hurdles as for other cancer types, the low prevalence of the disease in the general population, coupled with a notable lack of sensitive and specific biomarkers, have made the development of a clinically useful screening strategy particularly challenging. Here, we present a detailed review of the overall landscape of ovarian cancer diagnostics, with emphasis on emerging methods that employ novel protein, genetic, epigenetic and imaging-based biomarkers and/or advanced diagnostic technologies for the noninvasive detection of HGSC, particularly in women at high risk due to germline mutations such as BRCA1/2. Lastly, we discuss the translational potential of these approaches for achieving a clinically implementable solution for screening and diagnostics of early-stage ovarian cancer as a means of ultimately improving patient outcomes in both the general and high-risk populations.

show abstract

“…Carcinoembryonic antigen (CEA) is also a biomarker of ovarian cancer. Xu et al (2020) designed a dual-fluorescence probe that could detect CEA and CA125 simultaneously. When CEA or CA125 bound to the corresponding aptamer, the DNA-silver nanocluster-aptamer complexes were dragged from AuNPs, which caused AuNPs to aggregate and a fluorescent signal to be generated.…”

Section: Applications Of Aptamers In Ovarian Cancer Diagnosismentioning

confidence: 99%

Applications of Aptamers in the Diagnosis and Treatment of Ovarian Cancer: Progress From 2016 to 2020

Ruan

2021

Front. Genet.

View full text Add to dashboard Cite

Nucleic acid aptamers are short single-stranded DNA or RNA oligonucleotides selected from a random single-stranded nucleic acid library using systematic evolution of ligands by exponential enrichment technology. To allow them to bind to molecular targets with the same specificity and precision as that of antibodies, aptamers are folded into secondary or tertiary structures. However, compared to antibodies, aptamers are not immunogenic and are easier to synthesize. Furthermore, they are chemically modified, which protects them from degradation by nucleases. Hence, due to their stability and favorable targeting ability, aptamers are promising for the diagnosis and treatment of diseases. Ovarian cancer has the worst prognosis among all gynecological diseases and is usually diagnosed at the medium and advanced stages due to its nonspecific symptoms. Relapse is common, even if patients receive a standard therapeutic regimen including surgery and chemotherapy; simultaneously, drug resistance and adverse effects are reported in a several patients. Therefore, the safer and more efficient diagnostic and treatment method for ovarian cancer is imperative. Scientists have been trying to utilize aptamer technology for the early diagnosis and accurate treatment of ovarian cancer and some progress has been made in this field. This review discusses the screening of nucleic acid aptamers by targeting ovarian cancer cells and the application of aptamers in the diagnosis and treatment of ovarian cancer.

show abstract

Salt-induced gold nanoparticles aggregation lights up fluorescence of DNA-silver nanoclusters to monitor dual cancer markers carcinoembryonic antigen and carbohydrate antigen 125

Cited by 51 publications

References 48 publications

Surface-Defect-Induced and Synergetic-Effect-Enhanced NIR-II Electrochemiluminescence of Au–Ag Bimetallic Nanoclusters and Its Spectral Sensing

Surface-Defect-Induced and Synergetic-Effect-Enhanced NIR-II Electrochemiluminescence of Au–Ag Bimetallic Nanoclusters and Its Spectral Sensing

Current and Emerging Methods for Ovarian Cancer Screening and Diagnostics: A Comprehensive Review

Applications of Aptamers in the Diagnosis and Treatment of Ovarian Cancer: Progress From 2016 to 2020

Contact Info

Product

Resources

About